拟赴港上市，自然堂“珊珊来迟”

Core Viewpoint - Chando, a Chinese cosmetics brand, has submitted its IPO application to the Hong Kong Stock Exchange, aiming to enhance brand power and expand its brand matrix, amidst increasing reliance on its main brand and rising sales expenses [1][3][4]. Group 1: IPO and Market Position - Chando has officially submitted its IPO application, marking its entry into the capital market after 24 years of establishment, with Huatai International and UBS as joint sponsors [3][4]. - Unlike competitors like Proya and Marubi, which have already gone public, Chando's delayed IPO has raised industry speculation regarding its motivations, including financial independence and desire for greater control [3][4]. - The company claims to be the "third largest domestic cosmetics group in China," indicating its ambition to join the top tier of the industry [5][9]. Group 2: Financial Performance - Chando's revenue has shown consistent growth, with projected revenues of 42.92 billion, 44.42 billion, and 46.01 billion CNY for 2022, 2023, and 2024 respectively, reflecting growth rates of 3.49% and 3.58% for 2023 and 2024 [4][6]. - In the first half of 2025, Chando achieved revenue of 24.48 billion CNY, marking a year-on-year growth of 6.43% [4]. Group 3: Brand Dependency and Strategy - Chando's revenue heavily relies on its main brand, which accounted for 94.6%, 95.9%, and 95.4% of total revenue from 2022 to 2024, indicating a significant brand dependency [6][7]. - The company has several sub-brands, but their contribution to revenue is less than 10%, highlighting a lack of diversification [6][7]. - Experts suggest that Chando's IPO could provide solutions to its brand dependency issues through acquisitions and a more balanced multi-brand strategy [6][7]. Group 4: Sales and R&D Expenses - Chando's sales expenses have been high, with figures of 24.45 billion, 24.06 billion, and 27.16 billion CNY from 2022 to 2024, representing 57%, 54.2%, and 59% of annual revenue respectively [10]. - In contrast, R&D expenditures have been decreasing, with 1.2 billion CNY in 2022, dropping to 423.8 million CNY in the first half of 2025, indicating a declining focus on product development [10]. - The company plans to allocate part of the IPO proceeds to enhance R&D capabilities and expand its international presence [10][11].